Santhera Pharmaceuticals launches Raxone in its first EU market
Thursday, October 01, 2015
Santhera Pharmaceuticals Holding AG launches Raxone in its first EU market.
Launching Raxone for treatment of Leber's Hereditary Optic Neuropathy (LHON) in Germany, its first and largest EU market.
reuters.com
